Bendamustine/polatuzumab-vedotin/rituximabLack of efficacy following an off-label use: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2022年 / 1935卷 / 1期

关键词：

D O I：

10.1007/s40278-022-28908-6

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：113 / 113

相关论文

共 50 条

[21] MethylprednisoloneLack of efficacy following off-label use: case report
[J]. Reactions Weekly, 2022, 1902 (1) : 280 - 280
[22] ImiquimodLack of efficacy following off-label use: case report
[J]. Reactions Weekly, 2022, 1920 (1) : 254 - 254
[23] OmalizumabLack of efficacy following off-label use: case report
[J]. Reactions Weekly, 2023, 1956 (1) : 409 - 409
[24] EribulinLack of efficacy following off-label use: case report
[J]. Reactions Weekly, 2022, 1921 (1) : 135 - 135
[25] LorazepamLack of efficacy following off-label use: case report
[J]. Reactions Weekly, 2022, 1919 (1) : 354 - 354
[26] AzithromycinLack of efficacy following an off-label use: case report
[J]. Reactions Weekly, 2022, 1915 (1) : 92 - 92
[27] DexamethasoneLack of efficacy following off-label use: case report
[J]. Reactions Weekly, 2022, 1887 (1) : 259 - 259
[28] DexamethasoneLack of efficacy following off-label use: case report
[J]. Reactions Weekly, 2023, 1967 (1) : 143 - 143
[29] AntibacterialsLack of efficacy following off-label use: case report
[J]. Reactions Weekly, 2022, 1920 (1) : 43 - 43
[30] EculizumabLack of efficacy following off-label use: case report
[J]. Reactions Weekly, 2021, 1862 (1) : 196 - 196

← 1 2 3 4 5 →